Pembrolizumab for anaplastic thyroid cancer: a case study
- 22 October 2019
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 68 (12) , 1921-1934
Abstract
Blockade of the PD-1/PD-L1 pathway with targeted monoclonal antibodies has demonstrated encouraging anti-tumour activity in multiple cancer types. We present the case of a patient with BRAF-negative stage IVC anaplastic thyroid cancer (ATC) treated with the anti-PD-1 monoclonal antibody, pembrolizumab, following radiographic progression on chemoradiation. Blood samples were collected prior to and at four time points during treatment with pembrolizumab. Mass cytometry was used to determine expression of relevant biomarkers by peripheral blood mononuclear cells. Faecal samples were collected at baseline and 4 weeks following treatment initiation; taxonomic profiling using 16S ribosomal RNA (rRNA) gene sequencing was performed. Following treatment, a marked expansion in CD20+ B cell, CD16+ CD56lo NK cell and CD45RO+ CCR7+ central memory CD4+ T-cell populations was observed in the peripheral blood. Proportions of cells expressing the co-receptors TIGIT, OX40 and CD86 also increased during treatment. A high abundance of bacteria of the order Bacteroidales, specifically from the Bacteroidaceae and Rikenellaceae families, was identified in the faecal microbiota. Moreover, the patient’s microbiome was enriched in Clostridiales order members Ruminococcaceae, Veillonellaceae and Lachnospiraceae. Alpha diversity of the gut microbiome was significantly higher following initiation of checkpoint therapy as assessed by the Shannon and Simpson index. Our results suggest that treatment with pembrolizumab promotes expansion of T-, B- and NK cell populations in the peripheral blood at the time of tumour regression and have the potential to be implemented as predictive biomarkers in the context of checkpoint blockade therapy. Larger studies to confirm these findings are warranted.Keywords
Funding Information
- Cancer Council NSW (APP1147099)
- HMM Early Career Fellowship (GNT1037298)
- Cancer Institute New South Wales Future Research Leader Fellowship (-)
- Ingham Institute for Applied Medical Research
- CINSW translational cancer research centre CONCERT
- Liverpool Hospital
- Western Sydney University Postgraduate Scholarship
This publication has 77 references indexed in Scilit:
- The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancerOncoTargets and Therapy, 2013
- Sites of Metastases of Anaplastic Thyroid Carcinoma: Autopsy Findings in 45 Cases from a Single InstitutionThyroid®, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Anaplastic Thyroid CarcinomaFrontiers in Endocrinology, 2012
- An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaeaThe ISME Journal, 2011
- Results of combined treatment of anaplastic thyroid carcinoma (ATC)BMC Cancer, 2011
- Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and TreatmentJournal of Oncology, 2011
- QIIME allows analysis of high-throughput community sequencing dataNature Methods, 2010
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Identification of Bacteria in Formalin-Fixed, Paraffin-Embedded Heart Valve Tissue via 16S rRNA Gene Nucleotide SequencingJournal of Clinical Microbiology, 2006